PE20251184A1 - Conjugados anticuerpo-farmaco 5t4 y usos de los mismos - Google Patents

Conjugados anticuerpo-farmaco 5t4 y usos de los mismos

Info

Publication number
PE20251184A1
PE20251184A1 PE2024002516A PE2024002516A PE20251184A1 PE 20251184 A1 PE20251184 A1 PE 20251184A1 PE 2024002516 A PE2024002516 A PE 2024002516A PE 2024002516 A PE2024002516 A PE 2024002516A PE 20251184 A1 PE20251184 A1 PE 20251184A1
Authority
PE
Peru
Prior art keywords
antibody
alkyl
group
independently selected
independently
Prior art date
Application number
PE2024002516A
Other languages
English (en)
Spanish (es)
Inventor
Seema Kantak
Brian Alan Mendelsohn
Robyn M Barfield
Stepan Chuprakov
Penelope M Drake
Ayodele Ogunkoya
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of PE20251184A1 publication Critical patent/PE20251184A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2024002516A 2022-05-13 2023-05-10 Conjugados anticuerpo-farmaco 5t4 y usos de los mismos PE20251184A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263341957P 2022-05-13 2022-05-13
PCT/US2023/066811 WO2023220620A2 (en) 2022-05-13 2023-05-10 5t4 antibody-drug conjugates and uses thereof

Publications (1)

Publication Number Publication Date
PE20251184A1 true PE20251184A1 (es) 2025-04-23

Family

ID=88731090

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024002516A PE20251184A1 (es) 2022-05-13 2023-05-10 Conjugados anticuerpo-farmaco 5t4 y usos de los mismos

Country Status (16)

Country Link
US (1) US20250295803A1 (cg-RX-API-DMAC10.html)
EP (1) EP4522157A2 (cg-RX-API-DMAC10.html)
JP (1) JP2025516569A (cg-RX-API-DMAC10.html)
KR (1) KR20250024875A (cg-RX-API-DMAC10.html)
CN (2) CN119522097A (cg-RX-API-DMAC10.html)
AU (1) AU2023268538A1 (cg-RX-API-DMAC10.html)
CA (1) CA3252237A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024003441A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024015381A2 (cg-RX-API-DMAC10.html)
CR (1) CR20240491A (cg-RX-API-DMAC10.html)
DO (1) DOP2024000233A (cg-RX-API-DMAC10.html)
IL (1) IL316790A (cg-RX-API-DMAC10.html)
MX (1) MX2024013869A (cg-RX-API-DMAC10.html)
PE (1) PE20251184A1 (cg-RX-API-DMAC10.html)
TW (1) TW202408585A (cg-RX-API-DMAC10.html)
WO (1) WO2023220620A2 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250060248A (ko) * 2022-09-07 2025-05-07 엑셀리시스, 인코포레이티드 조직 인자 항체-약물 접합체 및 이의 용도
KR20260114567A (ko) * 2023-11-15 2026-07-22 엑셀리시스, 인코포레이티드 5t4 항체 약물 접합체 및 이의 사용 방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020006010A (es) * 2017-12-11 2020-10-16 Triphase Res And Development Iii Corp Conjugados de anticuerpo anti-cd22-maitansina, combinaciones y metodos de uso de los mismos.

Also Published As

Publication number Publication date
TW202408585A (zh) 2024-03-01
US20250295803A1 (en) 2025-09-25
WO2023220620A3 (en) 2023-12-14
CA3252237A1 (en) 2023-11-16
CR20240491A (es) 2025-01-07
KR20250024875A (ko) 2025-02-19
CO2024015381A2 (es) 2025-02-24
CN120571033A (zh) 2025-09-02
WO2023220620A2 (en) 2023-11-16
CN119522097A (zh) 2025-02-25
CL2024003441A1 (es) 2025-02-28
DOP2024000233A (es) 2025-02-28
MX2024013869A (es) 2024-12-06
IL316790A (en) 2025-01-01
JP2025516569A (ja) 2025-05-30
EP4522157A2 (en) 2025-03-19
AU2023268538A1 (en) 2024-11-21

Similar Documents

Publication Publication Date Title
AU2024203793B2 (en) Compounds comprising a linker for increasing transcyclooctene stability
CL2021000901A1 (es) Enlazadores de conjugación que contienen el grupo 2,3-diaminosuccinilo
PE20191837A1 (es) Sistema de administracion de liberacion sostenida que comprenden ligantes que no dejan huellas
BR112021026142A2 (pt) Composto conjugado ligado à cadeia lateral da fórmula, célula de tumor, composição farmacêutica, agente quimioterapêutico, e, agentes sinergísticos
PL360262A1 (pl) Kompozycje polimerycznych micelli
AR117657A1 (es) Conjugados de fármaco que comprenden anticuerpos y derivados de ecteinascidina
MX2021007706A (es) Conjugados de agonistas de receptor de reconocimiento de patron.
Feng et al. Biological functionalization of conjugated polymer nanoparticles for targeted imaging and photodynamic killing of tumor cells
PE20220764A1 (es) Conjugados de anticuerpo y farmaco
PE20221459A1 (es) Conjugados anticuerpo-farmaco dirigido a claudina 18.2
MX2019011957A (es) Conjugacion de un farmaco citotoxico con enlace bis.
PE20230467A1 (es) Conjugados de anticuerpo y farmaco de eribulina anti-mesotelina y metodos de uso
MXPA02011891A (es) Reacciones de adicion conjugadas para la entrega controlada de compuestos farmaceuticamente activos.
JP2023119064A (ja) 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート
MX2021010003A (es) Anticuerpos anti-mertk de alta afinidad y usos de los mismos.
MX2022000037A (es) Enlazadores hidrofilicos para conjugados de peptidos multivalentes.
AR123569A1 (es) Conjugados de pirrolobenzodiazepina-anticuerpo y usos de los mismos
PE20252686A1 (es) Conjugados de anticuerpo dll3-farmaco y usos de estos
MX2024015179A (es) Conjugados de anticuerpos y farmacos
MX2024014236A (es) Conjugados de anticuerpo-farmacos
WO2022011043A3 (en) Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer
MX2025007836A (es) Enlazadores, enlazadores de farmaco y conjugados de los mismos y metodos de uso de los mismos
CL2022002917A1 (es) Conjugados de anticuerpos de fármacos
MX2024012649A (es) Conjugados de ligando-farmaco con propiedades farmacocineticas y de liberacion de farmaco mejoradas
AR132067A1 (es) Compuestos de fármacos con una porción de unión de albúmina